Abeona Therapeutics (ABEO) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
12 Jun, 2026Commercial-stage cell and gene therapy platform
ZEVASKYN, an FDA-approved ex-vivo autologous gene therapy for RDEB, anchors the portfolio and demonstrates durable clinical benefit from a single application.
In-house CGMP manufacturing and regulatory expertise support a lean, scalable commercial model.
$168.3M in cash and equivalents as of March 31, 2026, provides financial stability.
Experienced leadership team with deep cell and gene therapy expertise.
ZEVASKYN clinical and commercial highlights
Demonstrates transformational wound healing and pain reduction, with no treatment-related serious adverse events over 12 years of follow-up.
Annual US revenue potential exceeds $250M, with a $4B cumulative opportunity.
6 activated Qualified Treatment Centers and payer coverage for 95% of commercially insured US lives.
Cash flow positive upon treating more than 3 patients per month.
Strong launch momentum and expanding treatment network.
RDEB disease and treatment impact
RDEB is a rare, severe monogenic skin disease causing fragile skin, chronic wounds, and high risk of complications.
ZEVASKYN is the first and only gene therapy using patients' own skin cells for durable wound healing in both children and adults.
Single application covers large wound areas and provides years of healing and pain relief.
Latest events from Abeona Therapeutics
- A 12.49 million-share resale shelf follows the ABO-801 acquisition and $30 million private placement.ABEO
Registration filing - ZEVASKYN launch ramp leads, with ABO-801 and partnered-program catalysts ahead.ABEO
Jefferies Global Healthcare Conference - ABO-801 adds a redesigned EoE Phase III program alongside ZEVASKYN’s expanding launch.ABEO
Stifel 2026 Healthcare Conference 2026 - Strong histologic results; exploratory DSQ mapping informs symptom endpoint strategy.ABEO
Clinical Development History presentation - ZEVASKYN’s $11.4M Q2 revenue anchors a broader cell- and gene-therapy pipeline.ABEO
Corporate presentation - ZEVASKYN revenue rose 18% QoQ as ABO-801 advanced toward Phase III.ABEO
Q3 2026 - ZEVASKYN launch accelerates with rising revenue, broad access, and a robust pipeline of gene therapies.ABEO
H.C. Wainwright 28th Annual Global Investment Conference - Durable gene therapy launch advances with expanding treatment centers and strong patient access.ABEO
Morgan Stanley 24th Annual Global Healthcare Conference - Steady ZEVASKYN rollout, robust coverage, and pipeline advances set stage for strong future growth.ABEO
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 ZEVASKYN revenue up 31% to $11.4M, NTAP status secured, net loss $20.2M, cash $146.8M.ABEO
Q2 2026